Description
The authors identify this conserved interface as a potential drug target but don’t demonstrate specificity or therapeutic efficacy. This represents a critical translational gap for developing HCN channelopathy treatments.
Gap type: open_question Source paper: Propofol rescues voltage-dependent gating of HCN1 channel epilepsy mutants. (2024, Nature, PMID:39085604)
Resolution criteria
Resolution requires: (1) cryo-EM or X-ray crystallography of HCN1 with methionine-phenylalanine interface bound to propofol or tamoxifen derivatives at resolution <=2.5 A, confirming binding pose at the target interface; (2) voltage-clamp electrophysiology measuring selectivity ratio (IC50 off-target / IC50 on-target) >=10-fold for HCN1 over HCN2/HCN4 in the same assay system; (3) in vivo efficacy in rodent models of epilepsy or neuropathic pain demonstrating therapeutic window (ED50 vs LD50) >=3-fold. Computational docking without experimental validation is insufficient.
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:18.824233+00:00”, “resolution_summary”: “Resolved by hypothesis h-d40d2659: HCN1-Mediated Resonance Frequency Stabilization Therapy. Supporting evidence includes debate sess_SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 3, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-d40d2659”, “title”: “HCN1-Mediated Resonance Frequency Stabilization Therapy”, “score”: 0.46, “reason”: “23 token overlaps; entity overlap: hcn, hcn1, hcn1-”, “analysis_id”: “sda-2026-04-01-gap-004”, “target_gene”: “HCN1”, “target_pathway”: “HCN channel / neuronal excitability”, “disease”: “neurodegeneration”, “composite_score”: 0.6477, “confidence_score”: 0.4, “status”: “debated”, “pubmed_evidence_ids”: [“27901476”, “36216854”, “37001612”, “37366350”, “39085604”]}, {“id”: “h-b3f9d8eb”, “title”: “HCN1-Selective Blockade Normalizes Thalamic Rebound Bursting in P/Q Channel Deficiency”, “score”: 0.434, “reason”: “15 token overlaps; entity overlap: hcn, hcn1, hcn1-”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-181156-feec7bd3”, “target_gene”: “HCN1”, “target_pathway”: “HCN channel / neuronal excitability / Ih current”, “disease”: “synaptic biology”, “composite_score”: 0.543188, “confidence_score”: 0.71, “status”: “proposed”, “pubmed_evidence_ids”: [“16728450”, “24953239”, “34018186”]}, {“id”: “h-var-6e963ed4e6”, “title”: “Closed-loop tACS targeting EC-II somatostatin interneurons to restore dendritic integration and prevent tau-mediated HCN channel dysfunction in AD”, “score”: 0.331, “reason”: “16 token overlaps; entity overlap: hcn, hcn1-”, “analysis_id”: “SDA-2026-04-03-26abc5e5f9f2”, “target_gene”: “SST”, “target_pathway”: “Entorhinal cortex layer II–III SST interneuron dendritic inhibition and HCN1-mediated theta resonance controlling dendritic integration and theta-gamma coupling in stellate cell networks”, “disease”: “Alzheimer’s disease”, “composite_score”: 0.564, “confidence_score”: 0.82, “status”: “promoted”, “pubmed_evidence_ids”: [“20641372”, “20641809”, “24841123”, “27534393”, “27929004”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2_task_9aae8fc5”, “title”: “While the abstract identifies AQP4 as a ‘potential and promising target’ and mentions it could provide ‘new therapeutic alternatives,’ the specific approaches for therapeutic modulation of AQP4 function are not defined. This represents a critical translational gap for moving from mechanistic understanding to clinical intervention.\n\nGap type: open_question\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.403, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-145358-185db2c8_20260414-005137”, “title”: “The study shows homozygous R136S fully rescues APOE4-driven pathology while heterozygous provides only partial protection, but the mechanistic basis for this gene dosage effect is unexplained. Understanding this mechanism is critical for developing therapeutic strategies that could mimic R136S protection.\n\nGap type: unexplained_observation\nSource paper: The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. (2023, Nature neuroscience, PMID:37957317)”, “score”: 0.387, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-145358-185db2c8”, “quality_score”: 0.81, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-193244-89904941_20260416-035819”, “title”: “The abstract identifies APOE4’s primary effect on oligodendrocyte cholesterol metabolism but doesn’t explain the mechanistic pathway. Understanding this mechanism is critical for developing targeted therapeutics that address the root cause rather than downstream effects.\n\nGap type: unexplained_observation\nSource paper: APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022, Nature, PMID:34788101)”, “score”: 0.375, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-193244-89904941”, “quality_score”: 0.69, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-142329-c1db787b_20260413-202651”, “title”: “The title suggests B cells actively maintain tolerance to AQP4, but the specific molecular mechanisms by which B cells prevent anti-AQP4 autoimmunity are not detailed. Understanding this tolerance mechanism is critical for developing targeted therapies for neuromyelitis optica.\n\nGap type: unexplained_observation\nSource paper: B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4. (2024, Nature, PMID:38383779)”, “score”: 0.371, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-142329-c1db787b”, “quality_score”: 0.79, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-173045-28238f1f”, “title”: “The study identifies KCNJ2 as a therapeutic target through CRISPR screening but doesn’t explain the mechanistic pathway by which this mechanosensory channel inhibition reduces neuronal death and proteinopathy. Understanding this mechanism is critical for rational drug development and predicting off-target effects.\n\nGap type: unexplained_observation\nSource paper: KCNJ2 inhibition mitigates mechanical injury in a human brain organoid model of traumatic brain injury. (2024, Cell stem cell, PMID:385”, “score”: 0.371, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-173045-28238f1f”, “quality_score”: 0.71, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}